Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN and 6 more

Show all authors

Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH

Acta pharmacologica Sinica26 Jan 2015Cited by 22 (Europe PMC)

PMID25619391PMCIDPMC4326793DOI10.1038/aps.2014.136PepBankPUB-25619391

Source link PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 24 weeks of add-on liraglutide significantly reduced mean body weight.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, body weight fell after 24 weeks of added liraglutide.
Peptide
Liraglutide
Outcome
DecreaseMean body weight
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Mean body weight
86.61 to 79.1 kg
before vs after liraglutide
Source sentences
Summary
Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939101
02HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 24 weeks of add-on liraglutide significantly reduced waist circumference.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, waist size fell after 24 weeks of added liraglutide.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Waist circumference
101.81 to 94.29 cm
before vs after liraglutide
Source sentences
Summary
waist circumference (from 101.81±13.96 to 94.29±14.17 cm)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939102
03HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 43.67% of patients lost 5%-10% of body weight on add-on liraglutide.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, 43.67% lost 5% to 10% of body weight on added liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBody weight loss of 5%-10%
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Patients with weight loss 5-10%
43.67%
24 weeks
Source sentences
Summary
resulting in body weight lose of 5%-10% in 43.67% patients
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939103
04HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 34.06% of patients lost more than 10% of body weight on add-on liraglutide.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, 34.06% lost more than 10% of body weight on added liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBody weight loss above 10%
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Patients with weight loss above 10%
34.06%
24 weeks
Source sentences
Summary
body weight loss above 10% in 34.06% patients
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939104
05HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes on add-on liraglutide, baseline waist circumference, BMI and HOMA-IR were independently correlated with body weight loss.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, baseline waist size, BMI and insulin resistance were linked to weight loss on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBaseline predictors of body weight loss
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939105
06HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 24 weeks of add-on liraglutide significantly decreased HbA1c.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, HbA1c fell after 24 weeks of added liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 328
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c
8.66 to 6.92%
before vs after liraglutide
Source sentences
Summary
liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939106
07HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, 35.37% of patients reached HbA1c below 7.0% on add-on liraglutide.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, 35.37% reached an HbA1c below 7.0% on added liraglutide.
Peptide
Liraglutide
Outcome
Not applicableHbA1c below 7.0%
Study
n = 328
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Patients with HbA1c below 7.0%
35.37%
24 weeks
Source sentences
Summary
with HbA1c<7.0% in 35.37% patients
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939107
08HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, liraglutide gave greater body weight loss in patients with a long duration of diabetes.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, those with long-standing diabetes lost more weight on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableWeight loss by duration of diabetes
Study
n = 328
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939108
09HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes, liraglutide gave better glycemic control in patients with a short duration of diabetes.
In plain wordsIn Chinese adults with overweight or obesity and type 2 diabetes, those with short-duration diabetes had better blood sugar control on liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGlycemic control by duration of diabetes
Study
n = 328
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
better glycemic control in patients with a short duration of diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939109
10HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes treated with liraglutide, patients with body weight loss above 10% had significantly lower plasma creatinine levels.
In plain wordsIn Chinese adults with obesity and type 2 diabetes, those who lost over 10% of body weight on liraglutide had lower creatinine levels.
Peptide
Liraglutide
Outcome
Not applicablePlasma creatinine in patients with body weight loss above 10%
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939110
11HumanNon-randomized trialEfficacy outcome
In Chinese overweight and obese adults with type 2 diabetes treated with liraglutide, patients who reached HbA1c below 7.0% had lower baseline HbA1c but higher baseline levels of C peptide and glucagon.
In plain wordsIn Chinese adults with obesity and type 2 diabetes, those reaching HbA1c below 7.0% on liraglutide had higher starting C peptide and glucagon.
Peptide
Liraglutide
Outcome
Not applicableBaseline C peptide and glucagon in patients reaching HbA1c below 7.0%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
with HbA1c<7.0% in 35.37% patients, who had a significantly lower baseline level of HbA1c, but higher baseline levels of C peptide and glucagon
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study.
Summary · context
The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments.
Report a problemFND-2561939111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.